None (BMRA) Valuation — DCF, Graham & Comparables

None (BMRA) — Price $2.37

Latest reported results:

Valuation dashboard for None (BMRA) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other peers companies.

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.

Analysis Summary

None reported revenue of $4.5M in the most recent fiscal year, growing at a 5-year CAGR of -9.2%.

Balance sheet quality for BMRA: current ratio of 1.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Price

Price$2.37
Market Cap$7M

Related companies: ALZN · CELZ · HSCS · IINN · LFWD · LUCY · PAVM

More sections of BMRA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks